Endovascular versus medical therapy for large-vessel anterior occlusive stroke presenting with mild symptoms.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 3 9 2019
medline: 5 8 2021
entrez: 3 9 2019
Statut: ppublish

Résumé

Acute ischemic stroke patients with a large-vessel occlusion but mild symptoms (NIHSS ≤ 6) pose a treatment dilemma between medical management and endovascular thrombectomy. To evaluate the differences in clinical outcomes of endovascular thrombectomy-eligible patients with target-mismatch perfusion profiles who undergo either medical management or endovascular thrombectomy. Forty-seven patients with acute ischemic stroke due to large-vessel occlusion, NIHSS ≤ 6, and a target-mismatch perfusion imaging profile were included. Patients underwent medical management or endovascular thrombectomy following treating neurointerventionalist and neurologist consensus. The primary outcome measure was NIHSS shift. Secondary outcome measures were symptomatic intracranial hemorrhage, in-hospital mortality, and 90-day mRS scores. The primary intention-to-treat and as-treated analyses were compared to determine the impact of crossover patient allocation on study outcome measures. Forty-seven patients were included. Thirty underwent medical management (64%) and 17 underwent endovascular thrombectomy (36%). Three medical management patients underwent endovascular thrombectomy due to early clinical deterioration. Presentation NIHSS ( Endovascular thrombectomy may pose an unfavorable risk-benefit profile over medical management for endovascular thrombectomy-eligible acute ischemic stroke patients with mild symptoms, which warrants a randomized trial in this subpopulation.

Sections du résumé

BACKGROUND
Acute ischemic stroke patients with a large-vessel occlusion but mild symptoms (NIHSS ≤ 6) pose a treatment dilemma between medical management and endovascular thrombectomy.
AIMS
To evaluate the differences in clinical outcomes of endovascular thrombectomy-eligible patients with target-mismatch perfusion profiles who undergo either medical management or endovascular thrombectomy.
METHODS
Forty-seven patients with acute ischemic stroke due to large-vessel occlusion, NIHSS ≤ 6, and a target-mismatch perfusion imaging profile were included. Patients underwent medical management or endovascular thrombectomy following treating neurointerventionalist and neurologist consensus. The primary outcome measure was NIHSS shift. Secondary outcome measures were symptomatic intracranial hemorrhage, in-hospital mortality, and 90-day mRS scores. The primary intention-to-treat and as-treated analyses were compared to determine the impact of crossover patient allocation on study outcome measures.
RESULTS
Forty-seven patients were included. Thirty underwent medical management (64%) and 17 underwent endovascular thrombectomy (36%). Three medical management patients underwent endovascular thrombectomy due to early clinical deterioration. Presentation NIHSS (
CONCLUSIONS
Endovascular thrombectomy may pose an unfavorable risk-benefit profile over medical management for endovascular thrombectomy-eligible acute ischemic stroke patients with mild symptoms, which warrants a randomized trial in this subpopulation.

Identifiants

pubmed: 31474193
doi: 10.1177/1747493019873510
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

324-331

Auteurs

Dylan N Wolman (DN)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

David G Marcellus (DG)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

Maarten G Lansberg (MG)

Stanford Health Care, Stanford Stroke Center, Stanford, CA, USA.

Gregory Albers (G)

Stanford Health Care, Stanford Stroke Center, Stanford, CA, USA.

Adrien Guenego (A)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

Michael P Marks (MP)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

Robert L Dodd (RL)

Stanford Healthcare, Department of Neurosurgery, Stanford, CA, USA.

Huy M Do (HM)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

Max Wintermark (M)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

Blake W Martin (BW)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

Jeremy J Heit (JJ)

Stanford Health Care, Department of Neuroimaging and Neurointervention, Stanford, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH